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Abstract
Background: Poor diet is thought to be a risk factor for many diseases, including age-related
macular disease (ARMD), which is the leading cause of blind registration in those aged over 60 years
in the developed world. The aims of this study were 1) to evaluate the dietary food intake of three
subject groups: participants under the age of 50 years without ARMD (U50), participants over the
age of 50 years without ARMD (O50), and participants with ARMD (AMD), and 2) to obtain
information on nutritional supplement usage.
Methods: A prospective cross-sectional study designed in a clinical practice setting. Seventy-four
participants were divided into three groups: U50; 20 participants aged < 50 years, from 21 to 40
(mean ± SD, 37.7 ± 10.1 years), O50; 27 participants aged > 50 years, from 52 to 77 (62.7 ± 6.8
years), and ARMD; 27 participants aged > 50 years with ARMD, from 55 to 79 (66.0 ± 5.8 years).
Participants were issued with a three-day food diary, and were also asked to provide details of any
daily nutritional supplements. The diaries were analysed using FoodBase 2000 software. Data were
input by one investigator and statistically analysed using Microsoft Excel for Microsoft Windows
XP software, employing unpaired t-tests.
Results: Group O50 consumed significantly more vitamin C (t = 3.049, p = 0.005) and significantly
more fibre (t = 2.107, p = 0.041) than group U50. Group ARMD consumed significantly more
protein (t = 3.487, p = 0.001) and zinc (t = 2.252, p = 0.029) than group O50. The ARMD group
consumed the highest percentage of specific ocular health supplements and the U50 group
consumed the most multivitamins.
Conclusions: We did not detect a deficiency of any specific nutrient in the diets of those with
ARMD compared with age- and gender-matched controls. ARMD patients may be aware of
research into use of nutritional supplementation to prevent progression of their condition.
Background
Poor diet is thought to be a risk factor for many diseases
[1,2]. One way of evaluating this risk is to carry out studies
using dietary assessment techniques. Food frequency
questionnaires (FFQ) have been the primary method of
food self-reporting in nutritional epidemiology for the
past 20 years, but it is now suggested that the ability to
study associations between diet and chronic diseases may
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be better served by using a food diary [3]. The most accu-
rate methods for dietary assessment are direct observation
in the home, or a food history, which involves a 1–2 hour
interview by a specially trained nutritionist. These meth-
ods are costly and the food diary is often used when they
are not possible [4].
Age-related macular degeneration (AMD) is the leading
cause of blind registration and visual disability in patients
over the age of 60 years in the developed World [5]. The
condition affects more than 1.75 million people in the
United States, and it is expected that the demographic
right-shift will lead to an increase in this number to
almost 3 million by 2020 [6]. In accordance with the
International Classification and Grading System for Age-
Related Maculopathy (ARM), and Age-Related Macular
Degeneration (AMD), these abbreviations will be used
throughout [7]. The term age-related macular disease
(ARMD) will be used to encompass ARM and AMD.
ARM is the early stage of ARMD and is most often clini-
cally apparent over the age of 50 years. The main symp-
tom is increasing difficulty with fine detail discrimination.
AMD is the later stage of ARMD and is categorised further
in to 'dry AMD' (also known as geographic atrophy, GA),
and 'wet AMD' (also known as 'neovascular', 'exudative',
or 'disciform' AMD) [7]. GA is the most common form,
and is estimated to be present in 15% of eyes by 80 years
of age [8-11]. Progression is slow and legal blindness has
been estimated to occur between 5 and 10 years [12]. Exu-
dative AMD is less common, occurring in 5.2% of the
population over 75 years [13], but accounts for a 90%
blind registrations[14]. Patients experience rapid, signifi-
cant loss of central vision as a result of growth of new
blood vessels beneath the retina.
The prevalence of GA and exudative AMD in the US pop-
ulation over 40 years of age has been estimated at 1.47%
[95% confidence interval (CI), 1.38% – 1.55%] [6]. The
likelihood of visual deterioration in those with exudative
AMD may be reduced with laser treatment [15-18],
although success is limited. The paucity of treatment
options has prompted interest in the identification of risk
factors, as well as the development of prevention strate-
gies. The three main risk factors are increasing age [19-26],
smoking [22,27-29], and genetic predisposition [30-34],
although other proposed factors include gender [35,36],
race [37-39], socioeconomic factors [21,40], cardiovascu-
lar disease [21,31,41,42], and poor nutrition [43-45].
It is thought that people with low systemic antioxidant
levels may be more prone to oxidative damage of the ret-
ina and therefore, AMD [46]. Oxidation refers to removal
of electrons and is mediated by reactive oxygen intermedi-
ates (ROI), which include free radicals, hydrogen perox-
ide, and singlet oxygen. Free radicals are molecules that
contain one or more unpaired electrons in their outer
orbits [47], and they extract electrons from other mole-
cules in order to achieve stability. These molecules are ren-
dered unstable by the interaction and a cytotoxic chain
reaction results. This damage is thought to contribute to
the pathogenesis of many diseases [1,2].
The hypothesised role of oxidation in the development of
AMD has prompted research into the use of nutritional
supplementation [48]. The Age-Related Eye Disease Study
(AREDS) found a significant odds reduction for the devel-
opment of advanced AMD with antioxidant plus zinc sup-
plementation [49], and the Lutein Antioxidant
Supplementation Trial (LAST) reported that visual func-
tion in AMD patients is improved with supplementation
of lutein and lutein combined with other nutrients [50].
Lutein and its isomer zeaxanthin are carotenoids, and are
synthesised in plants, algae, and bacteria. In mammalian
systems they can only be obtained from the diet [51].
Their selective absorption by the retina, in particular the
macula, is suggestive of a protective function, and has
prompted use of the term macular pigment (MP) to
describe them within the retina. Lutein and zeaxanthin
are believed to protect the retina in two ways. Firstly, they
act as blue-light filters. Action spectrum for blue-light
induced damage shows a maximum between 400 nm and
450 nm, and this is consistent with the absorption spec-
trum of macular pigment [52]. Secondly, they are able to
quench free radicals. Energy transfer to them quenches
singlet oxygen, and they are also believed to react with
peroxyl radicals that are involved with lipid peroxidation
[53].
The primary aim of this study was to evaluate the dietary
food intake of three subject groups: participants under the
age of 50 years without ARMD (U50), participants over
the age of 50 years without ARMD (O50), and partici-
pants with ARMD. The secondary aim was to obtain infor-
mation on nutritional supplement usage.
Methods
Study design
Prospective cross-sectional in a clinical practice setting.
Participants
Seventy-four participants gave informed consent to take
part in this study, which was approved by the Institutional
Human Ethics Committee. Recruitment methods
included sending information to Birmingham optome-
trists, ophthalmologists, and a specialist centre for reha-
bilitation of people with sight loss, an editorial in a local
newspaper, recruitment e-mails sent to the Royal National
Institute for the Blind (RNIB) and all staff and students at
Aston University and Aston Science Park, Birmingham,Nutrition Journal 2004, 3:16 http://www.nutritionj.com/content/3/1/16
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UK. For analysis the participants were divided into three
groups: U50; 20 participants aged < 50 years, from 21 to
40 (mean ± SD, 37.7 ± 10.1 years), O50; 27 participants
aged > 50 years, from 52 to 77 (62.7 ± 6.8 years), and
ARMD; 27 participants aged > 50 years with age-related
macular disease, from 55 to 79 (66.0 ± 5.8 years). All par-
ticipants were part of a larger study investigating the
effects of nutritional supplementation on visual function
in normal and diseased eyes [54].
Chi squared analysis for gender yielded no significant dif-
ference between groups U50 and O50 [χ2 (1) = 0.104 p =
0.305] and groups O50 and ARMD [χ2 (1) = 3.814 p =
0.051]. The difference in age is not significant between
groups O50 and ARMD (t = -1.842, p = 0.071).
Exclusion criteria were the presence of an ocular condition
other than ARMD and the presence of medical conditions
indicating a diet in which particular foods or food groups
were excluded (e.g. coeliac disease).
Participants were issued with a three-day food diary with
verbal and written instructions explaining that they
should add to their diary every time they eat or drink,
describing the food as accurately as possible and giving
estimates of amounts. They were also asked to provide
details of any daily nutritional supplements. The diary
consisted of two week days and one weekend day. The dia-
ries were analysed using FoodBase 2000 software (The
Institute of Brain Chemistry and Human Nutrition, 166–
220 Holloway Road, London N7 8DB, UK), which is a
computerised nutrition database containing data on
approximately 3750 foods. It can be used for recipe anal-
ysis, meal analysis, and daily or weekly analysis of menus
or food intakes. Data were input by one investigator and
statistically analysed using Microsoft Excel for Microsoft
Windows XP software, employing unpaired t-tests.
Results
Dietary analysis
The values for energy and nutrient intakes for all partici-
pants are shown in table 1.
Comparing group U50 with group O50
Group O50 consumed significantly more vitamin C (t =
3.049, p = 0.005) and significantly more fibre (t = 2.107,
p = 0.041) than group U50.
The mean intakes for men and women in each group are
shown in table 2. The data has been broken down into
male/female subgroups because reference nutrient intake
(RNI) data can differ with gender.
By tradition, investigators consider a study to be ade-
quately powered if it has an 80% chance of detecting a sig-
nificant difference when one exists. The number of study
participants needed to detect a clinically important differ-
ence with acceptable power, can be calculated using the
required power, the expected variability of the outcomes,
and the chosen probability of masking a type 1 error [55].
Power analysis shows that 20 subjects is not sufficient to
have an 80% chance of detecting a difference of 25% or
more of the mean value at the 5% level of significance
using the unpaired t-test for alcohol, copper, cholesterol,
selenium, vitamin E, vitamin D, and retinol equivalents.
In other words, for these dietary consitiuents we cannot
state whether we found no difference between groups
because there actually was no difference, or because the
Table 1: Daily mean and SD values for energy and nutrient intake.
Group U50 (mean ± SD) n = 20 Group O50 (mean ± SD) n = 27 Group ARMD (mean ± SD) n = 27
Energy (kcals) 1672.30 ± 425.58 1599.78 ± 331.50 1823.37 ± 546.18
Protein (g) 71.91 ± 27.62 68.14 ± 17.08 85.25 ± 18.28
Fat (g) 65.82 ± 27.77 58.44 ± 44.27 66.73 ± 21.76
Carbohydrate (g) 203.13 ± 39.46 204.43 ± 44.27 222.05 ± 82.66
Alcohol (g) 4.31 ± 4.38 4.83 ± 8.70 6.86 ± 9.54
Fibre (g) 13.04 ± 4.60 16.21 ± 5.44 17.31 ± 5.47
Cholesterol (mg) 192.19 ± 122.99 203.04 ± 82.63 242.60 ± 72.46
Zinc (mg) 8.43 ± 2.98 8.50 ± 2.58 10.07 ± 2.45
Copper (mg) 1.10 ± 0.52 1.21 ± 0.51 1.43 ± 0.54
Selenium (µg) 62.82 ± 75.84 105.01 ± 126.05 72.01 ± 62.76
Riboflavin (mg) 9.90 ± 35.82 1.57 ± 0.43 1.77 ± 0.44
Vitamin C (mg) 79.01 ± 40.67 140.59 ± 75.23 114.91 ± 60.01
Vitamin E (mg) 6.33 ± 3.49 6.71 ± 3.13 7.87 ± 3.52
Vitamin D (µg) 3.33 ± 3.06 3.05 ± 1.91 3.76 ± 2.54
Retinol equivalents (µg) 681.25 ± 499.55 679.44 ± 237.65 825.22 ± 440.54
% energy from fat 34.20 ± 7.34 32.56 ± 4.69 32.89 ± 5.60Nutrition Journal 2004, 3:16 http://www.nutritionj.com/content/3/1/16
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study did not have enough power to detect a difference.
The study was however, powered to assess the difference
in means for energy, protein, fat, carbohydrate, zinc, ribo-
flavin, and percentage energy from fat, and no significant
differences were found.
Comparing group O50 with group ARMD
Group ARMD consumed significantly more protein (t =
3.487, p = 0.001) and zinc (t = 2.252, p = 0.029) than
group O50 (see table 3). Power analysis shows that 27
subjects is not sufficient to have 80% chance of detecting
a difference in means of 25% at the 5% level of signifi-
cance using the unpaired t-test for alcohol, copper, choles-
terol, selenium, vitamin E, vitamin D, and retinol
equivalents. The study was powered to assess the differ-
ence in means for energy, fat, carbohydrate, fibre, ribofla-
vin, and percentage energy from fat, and found no
significant difference.
Baseline nutritional supplement intake
The results indicate that group O50 (mean ± SD; 1.44 ±
1.79) consumes significantly more types of nutritional
supplement than group U50 (0.55 ± 1.11) (t = 2.220, p =
0.032). No difference found between groups O50 and
ARMD, and the study was powered to have an 80%
chance of detecting a difference in means of 1 at the 10%
level of significance. The percentage of supplements taken
for each group is shown in figure 1.
Discussion
The aim of this study was to evaluate the dietary intakes of
three subject groups; U50, O50 and ARMD, as well as to
obtain information on nutritional supplement usage. Par-
ticipants under the age of 50 years consumed significantly
less dietary vitamin C than those aged over 50 years. Sup-
plementation data shows that 7.4 % of the O50 group
take uncombined vitamin C compared with 0% of the
U50 group. However, a higher percentage of the U50
group take multivitamins (33.3%) compared with the
O50 group (22.2%).
Vitamin C is water-soluble, is involved with several bio-
logical processes. As a reducing agent it is thought to be
active in protection against heart disease. It protects LDL
(low density lipoprotein) cholesterol from oxidative dam-
age and reduces platelet aggregation [56]. By enhancing
nitric oxide activity, vitamin C is potentially important in
lowering blood pressure [57].
High dose supplementation with an antioxidant and zinc
formulation, including vitamin C was associated with a
25% reduced risk of progression of AMD in those partici-
pants already suffering with the condition [49]. Some
studies, however, have found no evidence for a beneficial
role of vitamin C supplementation in ocular disease.
There was no relationship between cataract prevalence
and vitamin C intake in two studies [58,59], and no
relationship between cataract extraction and vitamin C
intake in a third [60].
Although the antioxidant properties of vitamin C are well
known, there is no clinical evidence suggesting that sup-
plementation with vitamin C can reduce the risk of
ARMD, or other ocular conditions such as cataract and
glaucoma. The RNI for men and women over the age of 18
years is 40 mg. The mean intakes of men and women in
Table 2: Mean vitamin C and fibre daily intake for groups U50 and O50
Mean vitamin C intake (mg) Mean fibre intake (g)
Women under 50 years (n = 12) 77.48 ± 42.79 12.19 ± 4.06
Women over 50 years (n = 22) 147.13 ± 75.12 16.03 ± 4.92
Men under 50 years (n = 12) 78.68 ± 36.93 14.18 ± 4.78
Men over 50 years (n = 7) 125.87 ± 78.20 15.96 ± 6.48
Table 3: Mean zinc and protein daily intake for groups O50 and AMD
Mean zinc intake (mg) Mean protein intake (g)
Women over 50 years (n = 22) 8.30 ± 2.50 66.35 ± 16.12
Men over 50 years (n = 7) 9.25 ± 2.50 71.61 ± 17.46
Women with ARMD (n = 13) 9.60 ± 2.26 78.05 ± 15.98
Men with ARMD (n = 14) 10.51 ± 2.54 91.93 ± 17.73Nutrition Journal 2004, 3:16 http://www.nutritionj.com/content/3/1/16
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the U50 and O50 groups are all above this value (table 2).
The higher intake values of the O50 group may be
explained by their increased awareness of the benefits of a
balanced diet, consumption by this group of more tradi-
tional, home prepared foods, and lower consumption of
convenience foods. An increased consumption of conven-
ience foods in the U50 group may also explain why they
consume significantly less fibre than the O50 group (t =
2.107, p = 0.041). Interestingly, all three groups had a
mean intake value of less than 18 g, the RNI for fibre in
men and women.
The ARMD group consumed significantly more dietary
zinc than age- and gender- matched controls. Zinc has
been investigated with regard to its potential preventative
role in ARMD. The AREDS group found a suggestive
reduction in the risk of progression of AMD in partici-
pants supplementing with 80 mg zinc daily. Previous ran-
domized controlled trials (RCTs) using 200 mg zinc daily
found conflicting results [61,62], and the positive result
reported by Newsome et al (1988) should be treated with
caution [48]. The higher intake by ARMD participants
may be explained by their awareness of research into zinc
supplementation and the condition. The RNI for women
over 18 years is 7.0 mg and for men over 18 years is 9.5
mg. Our results show that the mean intakes were above
RNI values for all four groups. Supplementation data
shows that 11.1 % of the ARMD participants supple-
mented with zinc, compared with 3.7 % of the O50
group, and 0 % of U50 participants. The Food Standards
Agency released a report on the safety of vitamins and
minerals in May 2003 and suggested a safe upper limit of
42 mg for total daily zinc intake. Zinc supplementation
over 150 mg/day has been associated with gastrointestinal
side effects such as cramping and nausea, as well as leth-
argy and blood in the urine [63]. Our results show that the
ARMD participants are most at risk of exceeding the safe
upper limit as they have the highest dietary and supple-
mental zinc intake.
The ARMD group consumed significantly more protein
than O50 participants. We are not aware of any investiga-
tion into a link between protein and risk of ARMD, and
table 4 shows that the mean intakes are above the RNI for
both men (55.5 g) and women (46.5 g).
Previous studies have found a relationship between
higher dietary fat intake and risk of ARM (RR 1.6) [64],
and high serum cholesterol and increased risk of exuda-
tive AMD compared with low serum cholesterol levels
[relative risk (RR) 4.1] [40,65]. However, the NHANES I
found that subjects with high cholesterol intake were less
likely to develop AMD than those with lower intake [odds
ratio (OR) 5.1] [21]. Our results show that ARMD partici-
pants consumed more fat and cholesterol than the O50
group, although these differences were not statistically sig-
nificant. The study was underpowered for cholesterol.
Research into the role of alcohol consumption in the
development of AMD has produced conflicting results.
Several studies have found no relation [40,66-70], but
consumption of beer has been related to an increased risk
of retinal pigmentation (OR 1.13) and exudative AMD
(OR 1.41) [71]. Both men (RR 2.16) and women (RR
2.20) in the highest category of wine intake (2 or more
glasses per day) have been shown to be at increased risk of
AMD [67]. This association was strongest with white wine,
and interestingly the NHANES I determined that red wine
Daily nutritional supplement use by group Figure 1
Daily nutritional supplement use by group.
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is associated with a lower risk of AMD [21]. This may be
related to the antioxidant properties of the phenolic com-
pounds within red wine [72]. Our data shows that the
ARMD group consumed more alcohol than both the U50
and O50 groups, although these differences were not sta-
tistically significant and the study was underpowered for
alcohol.
The non-significant differences found between groups for
alcohol, copper, cholesterol, selenium, vitamin E, vitamin
D, and retinol equivalents may have occurred because
there truly was no difference, or because the study had
insufficient power to detect a difference. Because of the
variability of the data, subject numbers required per group
for 80 % power at the 5 % significance level are 467 for
alcohol, 50 for copper, 44 for cholesterol, 341 for sele-
nium, 59 for vitamin E, 113 for vitamin D, and 71 for reti-
nol equivalents.
Multivitamins were the most commonly taken supple-
ment by the U50 group (30.0 %), compared with cod liver
oil for the both the ARMD group (33.3 %) and O50 par-
ticipants (22.2 %). Seventy-five percent of the specific
ocular health related supplements were taken by the
ARMD group, 25 % by the O50 group, and 0 % by the
U50 group.
Conclusion
We did not detect a deficiency of any specific nutrient in
the diets of those with ARMD compared with age- and
gender-matched controls. A higher percentage of ARMD
participants consume specific ocular health nutritional
supplements (33.3 %) compared with age- and gender-
matched controls (11.1 %) and U50 participants (0 %).
The U50 group consumed a higher percentage of multivi-
tamins, but significantly less vitamin C and fibre than the
O50 group. This suggests that the younger age-group
might use supplementation to ensure adequate consump-
tion of vitamins and minerals. The ARMD group con-
sumed more dietary zinc, more supplemental zinc, and
the highest percentage of ocular health related supple-
ments. This may suggest that information regarding the
results of studies investigating the role of nutritional sup-
plementation in reducing the risk of onset or progression
of AMD is reaching patients. These results however, may
be confounded by the fact that the ARMD participants
used in this study were enrolled in an RCT investigating
the use of nutritional supplementation in ARMD. Partici-
pants in research projects may be more aware of scientific
developments and more likely to investigate their condi-
tion and potential therapies.
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